Kara Palamountain is a co-founder,  at Minute Molecular Diagnostics, Inc. She is also the head of Marketing for Minute Molecular Diagnostics, Inc.

Palamountain has worked in diagnostics for over 15 years conducting market entry analysis for point-of-care diagnostics in over a dozen countries (Botswana, Brazil, Cambodia, China, India, Kenya, Lesotho, Malawi, Mozambique, Namibia, Nigeria, South Africa, Swaziland, Tanzania, Uganda, Vietnam and Zambia).

Ms. Palamountain is also the President of the Northwestern Global Health Foundation and a Research Associate Professor at the Kellogg School of Management (Kellogg). Prior to her work at the Northwestern Global Health Foundation and at Kellogg, Kara worked as a management consultant in Deloitte's Healthcare practice for over six years (1998-2002; 2004-2006). She received her MBA from Kellogg in 2004 and her BBA from the University of Texas at Austin in 1998.

Kara Palamountain

VP Marketing

  • Facebook
  • Twitter

Kara Palamountain is a co-founder,  at Minute Molecular Diagnostics, Inc. She is also the head of Marketing for Minute Molecular Diagnostics, Inc.

Palamountain has worked in diagnostics for over 15 years conducting market entry analysis for point-of-care diagnostics in over a dozen countries (Botswana, Brazil, Cambodia, China, India, Kenya, Lesotho, Malawi, Mozambique, Namibia, Nigeria, South Africa, Swaziland, Tanzania, Uganda, Vietnam and Zambia).

Ms. Palamountain is also the President of the Northwestern Global Health Foundation and a Research Associate Professor at the Kellogg School of Management (Kellogg). Prior to her work at the Northwestern Global Health Foundation and at Kellogg, Kara worked as a management consultant in Deloitte's Healthcare practice for over six years (1998-2002; 2004-2006). She received her MBA from Kellogg in 2004 and her BBA from the University of Texas at Austin in 1998.

Kara Palamountain

VP Marketing

  • Facebook
  • Twitter

Kara Palamountain is a co-founder,  at Minute Molecular Diagnostics, Inc. She is also the head of Marketing for Minute Molecular Diagnostics, Inc.

Palamountain has worked in diagnostics for over 15 years conducting market entry analysis for point-of-care diagnostics in over a dozen countries (Botswana, Brazil, Cambodia, China, India, Kenya, Lesotho, Malawi, Mozambique, Namibia, Nigeria, South Africa, Swaziland, Tanzania, Uganda, Vietnam and Zambia).

Ms. Palamountain is also the President of the Northwestern Global Health Foundation and a Research Associate Professor at the Kellogg School of Management (Kellogg). Prior to her work at the Northwestern Global Health Foundation and at Kellogg, Kara worked as a management consultant in Deloitte's Healthcare practice for over six years (1998-2002; 2004-2006). She received her MBA from Kellogg in 2004 and her BBA from the University of Texas at Austin in 1998.

Kara Palamountain

VP Marketing

Wine & Dessert Party

 Marc has 40 years of extensive leadership experience in the creation and commercialization of complex medical products for a worldwide market. These products are being used to today in hospitals, laboratories, clinics, physician offices and by patients at home around the world. 

Marc Minkus

VP Operations

  • Facebook
  • Twitter

Becca Kirby serves as a consultant for Minute Molecular Diagnostics, Inc.  She also serves as a Lecturer within Kellogg’s Public-Private Interface Initiative (KPPI) and as Market Access Director for NEST360° (Newborn Essential Solutions and Technologies). NEST360° works to reduce preventable newborn deaths in sub-Saharan Africa through the development of innovative technologies and the scaling of these life-saving medical devices across health systems. Prior to her work at Kellogg, Becca worked as a consultant in Deloitte’s healthcare practice.  She received her MBA from Kellogg and BBA from the University of Michigan’s Ross School of Business.

Becca Kirby

Marketing Consultant

  • Facebook
  • Twitter

© 2017 M2Dx Minute Molecular Diagnostics - All Rights Reserved

1800 Sherman Avenue Suite 504

Evanston, IL 60201

The Minute Molecular platform and tests are in development and are not yet authorized, cleared or approved for clinical use in the US.